ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0595

bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Abstract Number: 0596

Impact of a Multidisciplinary Rheumatology-Dermatology-Gastroenterology Center in the Management of Patients with Psoriatic Arthritis: Analysis of the First 5-years of Implementation
Abstract Number: 0597

Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Abstract Number: 0598

Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Abstract Number: 0599

Sex- related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
Abstract Number: 0600

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
Abstract Number: 0601

Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
Abstract Number: 0602

Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
Abstract Number: 0603

Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Abstract Number: 0604

Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
Abstract Number: 0605

Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Abstract Number: 0606

Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
Abstract Number: 0607

Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Abstract Number: 0608

Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Abstract Number: 0609

The Mediating Role of Trust in Usual Rheumatologists on the Relationship Between Multidimensional Health Literacy and Medication Adherence Among Japanese Systemic Lupus Erythematosus Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].